Effects of citronellal, a monoterpenoid in Zanthoxyli Fructus, on the intestinal absorption of digoxin in vitro and in vivo

Journal of Pharmaceutical Sciences

Volumn 95, Issue 3, 2006, Pages 552-560

  Yoshida, Naoko ^a   Takagi, Akiyoshi ^a   Kitazawa, Hidenori ^a   Kawakami, Junichi ^a   Adachi, Isao ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

Author keywords

Caco 2 cell; Citronellal; Digoxin; Intestinal absorption; Monoterpenoid; P glycoprotein; Pharmacokinetics; Rat; Zanthoxyli Fructus

Indexed keywords

CITRONELLAL; DIGOXIN; TERPENE;

ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTESTINE ABSORPTION; INTESTINE EPITHELIUM; TRANSCYTOSIS;

EID: 33645364144     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20563     Document Type: Review

References (33)

1. Zhang Y, Benet LZ. 2001. The gat as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40:159-168.
2. Bailey DG, Malcolm J, Arnold O, Spence JD. 1998. Grapefruit juice-drug interactions. Br J Clin Pharmacol 46:101-110.
3. Takanaga H, Ohnishi A, Matsuo H, Sawada Y. 1998. Inhibition of vinblastine efflux mediated by P-glycoprotein by grapefruit juice components in caco-2 cells. Biol Pharm Bull 21:1062-1066.
4. Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P. 1999. 6′,7′- Dihydroxybergamottin in grapefruit juice and Seville orange juice: Effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther 65:237-244.
5. Di Marco MP, Edwards DJ, Wainer IW, Ducharme MP. 2002. The effect of grapefruit juice and Seville orange juice on the pharmacokinetics of dextromethorphan: The role of gut CYP3A and P-glycoprotein. Life Sci 71:1149-1160.
6. Anuchapreeda S, Leechanachai P, Smith MM, Ambudkar SV, Limtrakul PN. 2002. Modulation of P-glycoprotein expression and function by curcumin in multidrug-resistant human KB cells. Biochem Pharmacol 64:573-582.
7. Chearwae W, Anuchapreeda S, Nandigama K, Ambudkar SV, Limtrakul P. 2004. Biochemical mechanism of modulation of human P-glycoprotein (ABCB1) by curcumin I, II, and III purified from Turmeric powder. Biochem Pharmacol 68:2043-2052.
8. Hennessy M, Kelleher D, Spiers JP, Barry M, Kavanagh P, Back D, Mulcahy F, Feely J. 2002. St. Johns wort increases expression of P-glycoprotein: Implications for drug interactions. Br J Clin Pharmacol 53:75-82.
9. Tsukamoto S, Tomise K, Miyakawa K, Cha BC, Abe T, Hamada T, Hirota H, Ohta T. 2002. CYP3A4 inhibitory activity of new bisalkaloids, dipiperamides D and E, and cognates from white pepper. Bioorg Med Chem 10:2981-2985.
10. Bhardwaj RK, Glaeser H, Becquemont L, Klotz U, Gupta SK, Fromm MF. 2002. Piperine, a major constituent of black pepper, inhibits human P-glycoprotein and CYP3A4. J Pharmacol Exp Ther 302:645-650.
11. Juliano RL, Ling V. 1976. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim Biophys Acta 455:152-162.
12. Inaba M, Kobayashi H, Sakurai Y, Johnson RK. 1979. Active efflux of daunorubicin and adriamycin in sensitive and resistant sublines of P388 leukemia. Cancer Res 39:2200-2203.
13. Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, Riordan JR. 1986. The mdr1 gene, responsible for multidrug-resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 141:956-962.
14. Ueda K, Cardarelli C, Gottesman MM, Pastan I. 1987. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. Proc Natl Acad Sci USA 84:3004-3008.
15. Higgins CF. 1992. ABC transporters: From microorganisms to man. Annu Rev Cell Biol 8:67-113.
16. Doige CA, Ames GF. 1993. ATP-dependent transport systems in bacteria and humans: Relevance to cystic fibrosis and multidrug resistance. Annu Rev Microbiol 47:291-319.
17. Gatmaitan ZC, Arias IM. 1993. Structure and function of P-glycoprotein in normal liver and small intestine. Adv Pharmacol 24:77-97.
18. Hebert MF. 1997. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev 27:201-214.
19. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB. 1997. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62:248-260.
20. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. 1998. Interaction of anti-HPV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acquir Immune Defic Syndr Hum Retrovirol 19:203-209.
21. Tsuruo T, Tomida A. 1995. Multidrug resistance. Anticancer Drugs 6:213-218.
22. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. 1999. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampicin. J Clin Invest 104:147-153.
23. Tanigawara Y, Okamura N, Hirai M, Yasuhara M, Ueda K, Kioka N, Komano T, Hori R. 1992. Transport of digoxin by human P-glycoprotein expressed in a porcine kidney epithelial cell line (LLC-PK1). J Pharmacol Exp Ther 263:840-845.
24. Tatro DS. 2005. Drug interaction facts. St. Louis: Facts and comparisons, Wolters Kluwer Health, Inc.
25. Westphal K, Weinberenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. 2000. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clin Pharmacol Ther 68:6-12.
26. Yoshida N, Takagi A, Kitazawa H, Kawakami J, Aadachi I. 2005. Inhibition of P-glycoprotein-mediated transport by extracts of and monoterpenoids contained in Zanthoxyli Fructus. Toxicol Appl Pharmacol 209:167-173.
27. Salphati L, Benet LZ. 1998. Effects of ketoconazole on digoxin absorption and disposition in rat. Pharmacology 56:308-313.
28. Takara K, Tsujimoto M, Ohnishi N, Yokoyama T. 2002. Digoxin up-regulates MDR1 in human colon carcinoma Caco-2 cells. Biochem Biophys Res Commun 292:190-194.
29. Wu CY, Benet LZ. 2005. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharm Res 22:11-23.
30. Varma MV, Khandavilli S, Ashokraj Y, Jain A, Dhanikula A, Sood A, Thomas NS, Pillai O, Sharma P, Gandhi R, Agrawal S, Nair V, Panchagnula R. 2004. Biopharmaceutic classification system: A scientific framework for pharmacokinetic optimization in drug research. Curr Drug Metab 5:375-388.
31. Mouly S, Pain MF. 2003. P-glycoprotein increases from proximal to distal regions of human small intestine. Pharm Res 20:1595-1599.
32. Sakai T, Yoshihara K, Hirose Y. 1968. Constituents of fruit oil from Japanese pepper. Bull Chem Soc Jpn 41:1945-1950.
33. Kodawara T, Masuda S, Wakasugi H, Uwai Y, Futami T, Saito H, Abe T, Inu K. 2002. Organic anion transporter oatp2-mediated interaction between digoxin and amiodarone in the rat liver. Pharm Res 19:738-743.